drugset / Trial / NCT00624195

Clinical Trial of CNS-targeted HAART (CIT2)

NCT00624195

RandomizedParallel-groupSingle-blindTreatment

Summary

CIT2 is a strategy for targeting HAART (Highly Active Antiretroviral Therapy) to the CNS (Central Nervous System) in patients with HIV associated neurocognitive impairment (HNCI). The primary goal of this study is to evaluate the effectiveness of CNS-targeted (CNS-T) as compared to non-CNS-targeted (non-CNS-T) HAART in treating HNCI globally and in different domains of functioning known to be affected by HIV. It is hypothesized that participants in the CNS-T arm will have greater improvement in neurocognitive functioning than those in the non-CNS-T arm. The secondary goal of the study is to compare participants assigned to CNS-T and non-CNS-T HAART on measures of CNS and systemic HIV suppression (undetectable CSF and plasma VL). It is also hypothesized that although CSF viral suppression will be more frequent in the CNS-T arm, plasma viral suppression will be similar in the two treatment arms.

Timeline

Start
2007-03
Primary completion
2012-02
Completion
2012-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Abacavir Other / unclassified
Subject Amprenavir Other / unclassified
Subject Atazanavir Other / unclassified
Subject Darunavir Small molecule
Subject Delavirdine Small molecule
Subject Efavirenz Other / unclassified
Subject Enfuvirtide Peptide
Subject Etravirine Small molecule
Subject Fosamprenavir Small molecule
Subject Lamivudine Other / unclassified
Subject Lopinavir Other / unclassified
Subject Maraviroc Other / unclassified
Subject Nelfinavir Other / unclassified
Subject Nevirapine Small molecule
Subject Raltegravir Other / unclassified
Subject Ritonavir Other / unclassified
Subject Saquinavir Small molecule
Subject Tenofovir Small molecule
Subject Tipranavir Small molecule
Subject Zidovudine Small molecule
Subject emtricitabine Other / unclassified